DnB Asset Management
CRNX

DnB Asset Management’s Crinetics Pharmaceuticals CRNX Stock Holding History

DnB Asset Management’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$721K Buy
19,273
+2,124
+12% +$79K ﹤0.01% 689
2026
Q1 		$623K Buy
17,149
+1,060
+7% +$47.3K ﹤0.01% 708
2025
Q4 		$749K Buy
16,089
+6,934
+76% +$309K ﹤0.01% 658
2025
Q3 		$381K Sell
9,155
-1,056
-10% -$33.8K ﹤0.01% 683
2025
Q2 		$294K Buy
10,211
+2,780
+37% +$85.9K ﹤0.01% 673
2025
Q1 		$249K Buy
+7,431
New +$278K ﹤0.01% 700

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JT
Jupiter Topco New York $245B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

DnB Asset Management's CRNX Position: Q2 2026 in Review

DnB Asset Management increased its Crinetics Pharmaceuticals (CRNX) stake by 12% in Q2 2026, buying an estimated $79K and bringing the position to 19,273 shares worth $721K. The position accounts for ﹤0.01% of the portfolio, ranked #689.

DnB Asset Management first reported a position in CRNX in Q1 2025 and has held it in 6 quarters since. The position peaked at $749K in Q4 2025. 267 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.

  • DnB Asset Management held 19,273 shares of Crinetics Pharmaceuticals worth $721K as of Q2 2026.
  • DnB Asset Management bought 2,124 Crinetics Pharmaceuticals shares in Q2 2026, an estimated $79K.
  • Crinetics Pharmaceuticals made up ﹤0.01% of DnB Asset Management's portfolio in Q2 2026, its #689 holding.
  • DnB Asset Management first reported a position in Crinetics Pharmaceuticals in Q1 2025 and has held it in 6 quarters since.
  • DnB Asset Management's Crinetics Pharmaceuticals position peaked at $749K in Q4 2025.
  • 267 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.

Based on DnB Asset Management's 13F filing for Q2 2026, filed 11 Aug 2026.